We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+15.6%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$8.4B
AUM Growth
+$1.66B
Cap. Flow
+$1.33B
Cap. Flow %
15.85%
Top 10 Hldgs %
61.33%
Holding
510
New
182
Increased
113
Reduced
52
Closed
146

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$79.7M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$74.4M
3
KVUE icon
Kenvue
KVUE
+$65.3M
4
ELF icon
e.l.f. Beauty
ELF
+$51.7M
5
GSK icon
GSK
GSK
+$46.6M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$96.3M
2
EXAS
Exact Sciences
EXAS
+$56.4M
3
PTCT icon
PTC Therapeutics
PTCT
+$34.5M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$28M
5
MDB icon
MongoDB
MDB
+$23M

Sector Composition

Rank Sector Weight
1 Healthcare 32.56%
2 Technology 5.44%
3 Consumer Discretionary 5.13%
4 Consumer Staples 2.69%
5 Communication Services 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GSK icon
26
GSK
GSK
$103B
$49M 0.58%
+1,000,000
New +$46.6M
ARGX icon
27
argenx
ARGX
$52B
$48.8M 0.58%
58,000
– –
S icon
28
CALL
SentinelOne
S
$6.87B
$48M 0.57%
3,200,000
+1,800,000
+129% +$29.5M
BABA icon
29
Alibaba
BABA
$305B
$46.8M 0.56%
319,100
+163,100
+105% +$26.6M
SBUX icon
30
Starbucks
SBUX
$118B
$46.3M 0.55%
549,805
+193,698
+54% +$16.3M
PENN icon
31
PENN Entertainment
PENN
$2.67B
$45.7M 0.54%
3,096,000
+992,334
+47% +$15.5M
OFIX icon
32
Orthofix Medical
OFIX
$496M
$40.1M 0.48%
2,648,000
+412,000
+18% +$6.29M
FIVN icon
33
FIVE9
FIVN
$2.22B
$40.1M 0.48%
2,000,000
– –
IRON icon
34
Disc Medicine
IRON
$2.93B
$39.7M 0.47%
499,391
+63,391
+15% +$5.36M
IMCR icon
35
Immunocore
IMCR
$1.65B
$38.1M 0.45%
1,098,000
+274,000
+33% +$9.67M
TMO icon
36
Thermo Fisher Scientific
TMO
$212B
$36.4M 0.43%
62,838
+7,822
+14% +$4.42M
S icon
37
SentinelOne
S
$6.87B
$36.3M 0.43%
2,422,219
+1,311,019
+118% +$21.5M
FIVN icon
38
CALL
FIVE9
FIVN
$2.22B
$36.1M 0.43%
1,800,000
+1,150,000
+177% +$24.4M
AVNS
39
DELISTED
Avanos Medical
AVNS
$35.9M 0.43%
3,200,000
+700,000
+28% +$8.01M
RIGL icon
40
Rigel Pharmaceuticals
RIGL
$693M
$35.8M 0.43%
836,000
+112,000
+15% +$4.22M
AUTL
41
Autolus Therapeutics
AUTL
$484M
$34.8M 0.41%
17,500,000
+1,900,000
+12% +$2.92M
ISRG icon
42
Intuitive Surgical
ISRG
$133B
$34.6M 0.41%
61,073
+20,073
+49% +$10.7M
DDOG icon
43
Datadog
DDOG
$97.4B
$33.3M 0.4%
244,537
+42,476
+21% +$6.71M
VERA icon
44
Vera Therapeutics
VERA
$2.31B
$33.1M 0.39%
653,796
+117,796
+22% +$4.18M
SNY icon
45
Sanofi
SNY
$103B
$32.8M 0.39%
676,000
+64,000
+10% +$3.17M
GTLB icon
46
GitLab
GTLB
$6.01B
$32.2M 0.38%
858,925
+482,067
+128% +$20.9M
AXGN icon
47
Axogen
AXGN
$2.46B
$30.6M 0.36%
936,000
-264,000
-22% -$6.49M
ANRO icon
48
Alto Neuroscience
ANRO
$1.06B
$27.3M 0.33%
1,536,000
-100,000
-6% -$1.26M
VSTM icon
49
Verastem
VSTM
$500M
$27.3M 0.32%
3,536,000
+1,440,000
+69% +$12.8M
HUBS icon
50
HubSpot
HUBS
$12.3B
$27.3M 0.32%
68,000
+22,982
+51% +$9.52M
1
2
3 4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return

Armistice Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Armistice Capital held 510 positions worth $8.4B, up 25% from $6.74B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Armistice Capital deployed $1.33B of net new capital in Q4 2025, opening 182 new positions and adding to 113 existing holdings. Its largest new stake was Kenvue: 3,992,196 shares worth $68.9M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 32% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $96.3M trimmed.

  • Armistice Capital's largest Q4 2025 buy was Kenvue: 3,992,196 shares worth $68.9M.
  • Armistice Capital added most to Agios Pharmaceuticals in Q4 2025, an estimated $79.7M increase.
  • Armistice Capital's biggest Q4 2025 reduction was Travere Therapeutics, cutting an estimated $96.3M.
  • Armistice Capital fully exited Exact Sciences in Q4 2025, selling an estimated $56.4M.
  • Armistice Capital's ten largest holdings make up 61% of its $8.4B portfolio in Q4 2025.
  • Armistice Capital opened 182 new positions and closed 146 in Q4 2025.
  • Armistice Capital's portfolio value rose 25% quarter-over-quarter to $8.4B.

Based on Armistice Capital's 13F filing for Q4 2025, filed 17 Feb 2026.